Rasmus Stilling Tougaard

The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Roni Nielsen
  • Anders Jorsal
  • Rasmus S. Tougaard
  • Jon J. Rasmussen, University of Copenhagen
  • ,
  • Morten Schou, University of Copenhagen
  • ,
  • Lars Videbaek, Univ Southern Denmark, University of Southern Denmark, Odense University Hospital, Odense Univ Hosp, Dept Cardiol
  • ,
  • Ida Gustafsson, Fredriksberg Univ Hosp, Dept Cardiol
  • ,
  • Jens Faber, Herlev Gentofte Univ Hosp, Dept Endocrinol
  • ,
  • Allan Flyvbjerg, Steno Diabet Ctr Copenhagen, Steno Diabetes Center
  • ,
  • Henrik Wiggers
  • Lise Tarnow, Steno Diabet Ctr Sjaelland
  • ,
  • Caroline Kistorp, University of Copenhagen

Aim To assess the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). Materials and methods In the LIVE study, patients (n = 241) with left ventricular ejection fraction

Original languageEnglish
JournalDiabetes, Obesity and Metabolism Online
Number of pages10
ISSN1462-8902
DOIs
Publication statusE-pub ahead of print - Jul 2020

    Research areas

  • GLP-1 analogue, heart failure, type 2 diabetes, CARDIOVASCULAR EVENTS, POTASSIUM EXCRETION, PROGNOSTIC VALUE, URINARY SODIUM, DOUBLE-BLIND, ADRENOMEDULLIN, MORTALITY, COPEPTIN, BIOMARKERS, NEUROHORMONES

See relations at Aarhus University Citationformats

ID: 195038022